Axcella surges on FDA's nod to begin human study for long COVID fatigue treatment

Axcella Health

16/02/2023 11:48

** Shares of drug developer Axcella Health Inc  AXLA.O 
surge 42% premarket to 85 cents, top gainer across U.S.
exchanges 
    ** Co said late on Wednesday the U.S. FDA cleared the
application to begin mid to late-stage study in the U.S. for
AXA1125 in the treatment of Long COVID Fatigue
    ** The mid- to late-stage study will enroll participants who
have had fatigue for at least 12 weeks after COVID-19 infection
and measure the main goal of improvements in fatigue 
    ** Study design now accepted by U.S. and U.K. regulatory
authorities - AXLA
    ** The application was based on a mid-stage study which
found patients who received AXA1125 experienced  clinically and
statistically significant improvement in mental and physical
fatigue scores compared to placebo
   ** Co lost ~84% in 2022
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))